| Description | Mupadolimab (CPI-006) is a humanized FC-γR binding deficient IgG1 anti-CD73 antibody with potential anticancer activity and activation of CD73POS B cells. |
| In vitro | Mupadolimab 诱导增加与 B 细胞成熟和抗原呈递相关的标记物表达，转化为浆细胞，以及 IgM 和 IgG[1] 的分泌增加。 |
| In vivo | Mupadolimab（10 mg/kg；腹腔内注射；每日一次，连续15天）在感染SARS-CoV-2的NSG-SGM3小鼠中刺激特异性抗原的体液免疫反应[1]。 |
| Synonyms | CPI-006 |
| molecular weight | N/A |
| CAS | 2451856-97-4 |
| Storage | store at low temperature | store at -80°C |
| References | 1. Miller R A, et al. Clinical results with a B cell activating anti-CD73 antibody for the immunotherapy of Covid-19. medRxiv, 2021. |